GlassScriptPhysician profile
Richard S Margolis
NPI 1043201429
$376.71
in general payments reported to CMS, 2019-2025
14 companies · $27.01 in 2025
The $27.01 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $82.04 · 2021: $39.40 · 2022: $4.30 · 2023: $20.90 · 2025: $27.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $73.53 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Abbvie INC. | $72.55 | 2019 | |
| Therapeuticsmd, INC. | $42.29 | 2020-2021 | |
| Allergan, INC. | $32.91 | 2019-2020 | |
| Pfizer INC. | $31.30 | 2019-2021 | |
| Becton, Dickinson and Company | $22.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2020 | |
| Lupin INC. | $17.11 | 2019 | |
| Astellas Pharma US INC | $16.85 | 2019 | |
| Merck Sharp & Dohme LLC | $16.84 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.40 | 2019 | |
| Millicent US INC | $11.57 | 2019 | |
| Organon LLC | $4.30 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.